Case Study 21.2 — Hernandez Goes Global

A composite, illustrative case. Dr. Hernandez and the consortium are composites built to teach the international-research sub-world; the structures are real. Verify specifics with any actual funder.

Why this case: the research sub-world

Case Study 21.1 followed a local development organization. This case follows the research sub-world of international funding — because "international funding" is not one thing, and a multi-country research consortium operates on a different logic from a development grant. We return to Dr. Hernandez, whose diabetes text-message adherence intervention (Chapter 16) succeeded in a U.S. randomized trial. She now wants to know whether it works across very different health systems and cultures — a question that can only be answered with a multi-country study, and that points her toward international research funding.

Step 1 — Reading the sub-world (Section 21.5, Going Deeper)

Hernandez first recognizes which sub-world she's entering. A cross-border research-and-innovation program (such as the EU's, which funds multi-country science) rewards scientific excellence, a consortium of research institutions across countries, work packages, and impact pathways — closer to the NIH/NSF world (Chapters 16–17) with a cross-border consortium added, and with its own elaborate portal, partner-search tools, and budget rules. This is not a development logframe grant, and pitching it like one would misread the room. Hernandez studies the program's actual priorities and rules before writing.

Step 2 — Building the consortium (Section 21.3)

International research funding makes the consortium the fundable unit. Hernandez must:

  • Assemble research institutions across several countries, each able to lead the work in its own setting.
  • Designate a lead/coordinating institution that holds the prime relationship with the funder and the fiduciary responsibility for funds flowing to all partners.
  • Divide the project into work packages, with partners responsible for each.

But the chapter's deeper lesson reaches even here. It would be easy — and wrong — for Hernandez to treat her in-country partners as mere data-collection sites executing her U.S.-designed protocol. The localization logic applies to research too: a credible international study centers the in-country investigators' expertise and leadership, because they understand their own health systems, languages, and cultural contexts in ways Hernandez cannot. Adapting a text-message adherence intervention across cultures is not a translation task; it's a co-design task. So Hernandez builds the consortium with in-country partners as genuine co-investigators shaping the design, not as subcontracted enrollers. This is both more ethical and better science — and funders increasingly expect it.

Step 3 — The cross-border machinery (Sections 21.4–21.6)

Hernandez confronts the layers that domestic NIH work never required:

  • A results-and-impact framework (logframe-like) specifying objectives, indicators, and impact pathways across the consortium.
  • Multi-currency budgeting across partner countries, with exchange-rate risk over a multi-year project.
  • Ethics approvals in every jurisdiction — each country's research-ethics and data-protection requirements, not just one institutional review board.
  • Data governance across borders — how patient data is handled, shared, and protected under multiple legal regimes.
  • Coordination across time zones, languages, and institutional cultures — itself real, fundable work that must be budgeted and staffed.

Her excellent science, by itself, is no longer sufficient. The consortium and its cross-border accountability are now part of what she must build and prove.

Step 4 — What stays the same

Importantly, the universal craft still holds. Hernandez's specific aims thinking (Chapter 6), her rigorous approach (Chapter 9), her evaluation design (Chapter 10), and her attention to the funder's real priorities (Chapter 2) all carry over. International research funding doesn't replace the universal proposal; it wraps it in a consortium, a cross-border accountability framework, and multi-jurisdiction compliance. The engine is the same; the chassis is the most elaborate she's built.

What this case teaches

  1. Read the sub-world. International research funding rewards scientific excellence and consortia, not a development logframe — identify which international sub-world you're in and write to its logic.
  2. The consortium is the unit. Multi-country research is funded as a partnership with a coordinating lead and work packages, not as a lone PI's project.
  3. Localization applies to research too. In-country partners are co-investigators whose contextual expertise shapes the design — not data-collection sites — which is both more ethical and better science.
  4. New compliance layers, same craft. Multi-currency budgets, ethics approvals in every jurisdiction, and cross-border data governance are added on top of the universal proposal craft, which still carries the science.

🔄 Retrieve: Without rereading, name (a) what the international research sub-world most rewards (versus a development grant), and (b) why treating in-country partners as data-collection sites would be both unethical and scientifically weaker. (Answers above.)